On December 30, 2022, Pluristem Therapeutics, Inc closed the transaction. The company amended the terms of the transaction. The company has received $8,469,323 pursuant to exemption provided under Regulation D form 14 investors.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.86 USD | -1.68% | +1.91% | +26.40% |
May. 02 | Pluri Inc. Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment | CI |
May. 02 | Pluri Inc. Announces Appointments to Its Scientific Advisory Board | CI |
1st Jan change | Capi. | |
---|---|---|
+26.40% | 32.12M | |
+17.69% | 47.02B | |
+48.77% | 41.86B | |
+1.02% | 41.76B | |
-4.27% | 28.8B | |
+11.89% | 26.05B | |
-21.42% | 19.15B | |
+4.29% | 12.55B | |
+28.28% | 12.34B | |
-4.43% | 11.82B |
- Stock Market
- Equities
- PLUR Stock
- News Pluri Inc.
- Pluri Inc. announced that it has received $8.469323 million in funding